topiramate vs semaglutide What is the evidence regarding the safety of new obesity pharmacotherapies Phentermine vs Ozempic (Semaglutide): Uses

In June 2025, Eli Lilly reported Phase III ACHIEVE-1 Survodutide (BI 456906): Boehringer Ingelhium Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium

HOMA2-IR, a critical indicator of insulin resistance, enhanced at doses of 4 mg or higher

The review, titled "Optimizing Nitric Oxide Production for Exercise Performance and Vascular Function: A Narrative Review on the Combination of Glutathione and Citrulline," emphasises how this pairing supports improved nitric oxide production, which is vital for circulation, vascular health and exercise performance

Quantitative real-time PCR

There is sufficient evidence supporting that pharmacotherapy in combination with behavior-based interventions can result in significant weight loss and improved cardiometabolism